In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...
Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation ...
The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $59.00 expecting TECH to rise to within 12 months (a possible ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) ...
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...
(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Shares of Bio-Techne Corp. TECH slid 2.00% to $57.82 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.04% to 6,881.62 and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results